アブストラクト
Japanese
Title | Parkinson病及び関連疾患の治療の進歩 (2019) |
---|---|
Subtitle | 特集 神経疾患治療の進歩2019 - 4 |
Authors | 王子悠**, 服部信孝** |
Authors (kana) | |
Organization | **順天堂大学医学部神経学講座 |
Journal | 神経治療学 |
Volume | 37 |
Number | 5 |
Page | 728-731 |
Year/Month | 2020 / |
Article | 報告 |
Publisher | 日本神経治療学会 |
Abstract | 「はじめに」Parkinson病(Parkinson disease:PD)の治療は薬物治療を基本とするが, 近年デバイス療法である磁器刺激療法や経頭蓋直流電流刺激療法の有効性も多く報告されている. そして運動療法も新たな知見が得られている. さらに非運動症状に対しても様々な治療アプローチが試みられている. 本稿では2019年に発表された論文からPDおよびdouble-bind, randomized controlled trialで有効性が示されたものを中心に解説する. 「I. PDの治療法」「1. 運動症状に対する薬物療法」「1) 吸入用L-ドパ」PDのオフ時間の治療に用いられる新規L-ドパ吸入粉末薬(CVT-301)の効果・安全性を検証する第III相二重盲検ランダム化試験では, 1日のオフ時間が2時間以上でL-ドパ/脱炭酸酵素阻害薬で治療を受けている30〜85歳のPD患者でCVT-301 60mg, CVT-301 84mg, またはプラセボに1:1:1の割合で無作為に割り付けられた. |
Practice | 臨床医学:内科系 |
Keywords | Parkinson disease, motor symptom, non-motor symptom, disease modifying therapy |
English
Title | Review / Advanced in Neurological Therapeutics (2019). Parkinson's disease and related disorders |
---|---|
Subtitle | |
Authors | Yutaka OJI, Nobutaka HATTORI |
Authors (kana) | |
Organization | Department of Neurology, Juntendo University School of Medicine |
Journal | Neurological Therapeutics |
Volume | 37 |
Number | 5 |
Page | 728-731 |
Year/Month | 2020 / |
Article | Report |
Publisher | Japanese Society of Neurological Therapeutics |
Abstract | We review reports published in 2019 providing new information on the management of Parkinson's disease (PD). L-dopa inhalation powder and sublingual apomorphine are effective on the motor symptom of off-state of PD patients. Rasagiline is safe and effective in monotherapy for patients with early-stage of PD. Zonisamide is effective against parkinsonism in patients with dementia with Lewy bodies (DLB). An oral preparation of nicotine has a significant improvement in scores of falls and freezing gait. Nicotine gum is effective for hypotension in PD patients. Fesoterodine improved nocturia and urinary urgency in PD patients. Percutaneous vagal nerve stimulation for PD patients with gastrointestinal complaints is a potential device for the non-invasive improvement of gastrointestinal symptoms. Incobotulinumotoxin A is effective on PD hypersalivation. Vinpocetine and intranasal insulin are effective for symptoms of cognitive impairment of PD. Aerobic exercise using gamed-virtual reality software and body weight supported treadmill training (BWSTT) were reported to be effective for PD. Probiotics significantly improved PD symptoms, and a significant improvement effect of licorice on motor symptoms was also reported. Treatment methods using medical devices are also advancing, such as Proprioceptive Focal Stimulation (Equistasi(R)) by nanotechnology equipment, high-frequency repetitive transcranial magnetic stimulation (rTMS), transcranial direct current stimulation (tDCS), and transcranial alternating current stimulation (tACS) have been reported. Simultaneous stimulation of the subthalamic nucleus (STN) and substantia nigra reticulata (SNr) is effective for restless leg syndrome and nocturnal motor symptoms. A method that directly targets the dentatoruburothamic tract (DRTT) under the guidance of diffusion tensor imaging and tractography (DTIT) improves the tremor of PD patients. Finally, caloric vestibular stimulation (CVS) using a device called Thermo Neuro Modulation (TNM(TM)) improves motor and non-motor symptoms of PD. |
Practice | Clinical internal medicine |
Keywords | Parkinson disease, motor symptom, non-motor symptom, disease modifying therapy |
- 全文ダウンロード: 従量制、基本料金制の方共に770円(税込) です。
参考文献
- 1) LeWitt PA et al : Lancet Neurol 18 : 145-154
- 2) Hauser RA et al : Parkinsonism Relat Disord 64 : 175-180
- 3) Olanow CW et al : Lancet Neurol 19 : 135-144
- 4) Hattori N et al : Parkinsonism Relat Disord 60 : 146-152
- 5) Murata M et al : Parkinsonism Relat Disord 76 : 91-97
残りの22件を表示する
- 6) Lieberman A et al : Front Neurol 10 : 424
- 7) DiFrancisco-Donoghue J et al : Nicotine Tob Res 21 : 253-256
- 8) Yonguc T et al : World J Urol 38 : 2013-2019
- 9) Kaut O et al : NeuroRehabilitation 45 : 449-451
- 10) Jost WH et al : Neurology 92 : e1982-e1991
- 11) Jost WH et al : Parkinsonism Relat Disord 70 : 23-30
- 12) Ping Z et al : Neurol Sci 40 : 113-120
- 13) Novak P et al : PLoS One 14 : e0214364
- 14) Raymackers JM et al : Acta Neurol Belg 119 : 607-613
- 15) van der Kolk NM et al : Lancet Neurol 18 : 998-1008
- 16) Atan T et al : Turk J Med Sci 49 : 999-1007
- 17) Tamtaji OR et al : Clin Nutr 38 : 1031-1035
- 18) Petramfar P et al : J Ethnopharmacol 247 : 112226
- 19) Peppe A et al : Front Neurol 10 : 998
- 20) Khedr EM et al : Neurorehabil Neural Repair 33 : 442-452
- 21) Mi TM et al : Parkinsonism Relat Disord 68 : 85-90
- 22) Adenzato M et al : Transl Neurodegener 8 : 1
- 23) Bueno MEB et al : Neurosci Lett 696 : 46-51
- 24) Del Felice A et al : Neuroimage Clin 22 : 101768
- 25) Hidding U et al : Parkinsonism Relat Disord 62 : 141-147
- 26) Low HL et al : Clin Neurol Neurosurg 185 : 105466
- 27) Wilkinson D et al : Parkinsonism Relat Disord 65 : 261-266